Key features and details
- Expression system: Escherichia coli
- Purity: > 95% SDS-PAGE
- Active: Yes
- Tags: His tag N-Terminus
- Suitable for: Functional Studies, SDS-PAGE
Product nameRecombinant human Nmnat1/NMNAT protein
See all Nmnat1/NMNAT proteins and peptides
Specific Activity: ≥4200 pmol/min/µg
50 μL reaction mixture contained 50 mM Tris-HCl, pH 7.4, 5 mM MgCl2, 0.1 mM NMN, 0.1 mM ATP and various amounts of NMNAT. The reaction was incubated at 37°C for 30 minutes and the amount of ATP consumed was calculated.
Purity> 95 % SDS-PAGE.
Expression systemEscherichia coli
Protein lengthFull length protein
SequenceMHHHHHHENSEKTEVVLLACGSFNPITNMHLRLFELAKDYMNGTGRYTVV KGIISPVGD AYKKKGLIPAYHRVIMAELATKNSKWVEVDTWESLQKEW KETLKVLRHHQEKLEASDC DHQQNSPTLERPGRKRKWTETQDSSQKKS LEPKTKAVPKVKLLCGADLLESFAVPNL WKSEDITQIVANYGLICVTR AGNDAQKFIYESDVLWKHRSNIHVVNEWIANDISSTKIRRA LRRGQSI RYLVPDLVQEYIEKHNLYSSESEDRNAGVILAPLQRNTAEAKT
Predicted molecular weight33 kDa including tags
Amino acids2 to 279
TagsHis tag N-Terminus
Our Abpromise guarantee covers the use of ab198473 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
This product was previously labelled as Nmnat1
Concentration information loading...
Preparation and Storage
Stability and Storage
Shipped on Dry Ice. Store at -80°C. Avoid freeze / thaw cycle.
Preservative: 1.74% Imidazole
Constituents: 0.63% Tris HCl, 0.64% Sodium chloride, 0.02% Potassium chloride, 0.04% Tween, 20% Glycerol
This product is an active protein and may elicit a biological response in vivo, handle with caution.
- EC 22.214.171.124
- Leber's congenital amaurosis 9
FunctionCatalyzes the formation of NAD(+) from nicotinamide mononucleotide (NMN) and ATP (PubMed:17402747). Can also use the deamidated form; nicotinic acid mononucleotide (NaMN) as substrate with the same efficiency (PubMed:17402747). Can use triazofurin monophosphate (TrMP) as substrate (PubMed:17402747). Also catalyzes the reverse reaction, i.e. the pyrophosphorolytic cleavage of NAD(+) (PubMed:17402747). For the pyrophosphorolytic activity, prefers NAD(+) and NaAD as substrates and degrades NADH, nicotinic acid adenine dinucleotide phosphate (NHD) and nicotinamide guanine dinucleotide (NGD) less effectively (PubMed:17402747). Involved in the synthesis of ATP in the nucleus, together with PARP1, PARG and NUDT5 (PubMed:27257257). Nuclear ATP generation is required for extensive chromatin remodeling events that are energy-consuming (PubMed:27257257). Fails to cleave phosphorylated dinucleotides NADP(+), NADPH and NaADP(+) (PubMed:17402747). Protects against axonal degeneration following mechanical or toxic insults.
Tissue specificityWidely expressed with highest levels in skeletal muscle, heart and kidney. Also expressed in the liver pancreas and placenta. Widely expressed throughout the brain.
PathwayCofactor biosynthesis; NAD(+) biosynthesis; NAD(+) from nicotinamide D-ribonucleotide: step 1/1.
Cofactor biosynthesis; NAD(+) biosynthesis; deamido-NAD(+) from nicotinate D-ribonucleotide: step 1/1.
Involvement in diseaseLeber congenital amaurosis 9
Sequence similaritiesBelongs to the eukaryotic NMN adenylyltransferase family.
- Information by UniProt
To our knowledge, customised protocols are not required for this product. Please try the standard protocols listed below and let us know how you get on.
ab198473 has not yet been referenced specifically in any publications.